跳至主要内容
临床试验/NCT04932447
NCT04932447进行中(未招募)不适用

Time-efficient Inspiratory Muscle Strength Training for Improving Blood Pressure and Vascular Function in Older Adults With Sleep Disordered Breathing

University of Arizona2 个研究点 分布在 1 个国家目标入组 122 人开始时间: 2021年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
122
试验地点
2
主要终点
Change from baseline casual Systolic Blood Pressure at 24 weeks, 28 weeks, and 36 weeks

研究概览

简要总结

This clinical research study will investigate the effects of respiratory strength training on blood pressure and cardiovascular health in adults who are 50 years of age and older and have been diagnosed with moderate or severe obstructive sleep apnea.

详细描述

Exercise has well-documented benefits for systolic blood pressure (SBP) and cardiovascular health. Whereas current guidelines advocate ~150 min moderate intensity exercise/week, our preliminary data show ~5 min/day of inspiratory muscle strength training (IMST) for 6 weeks lowers casual (resting) SBP by ~12 mmHg.

This simple approach to lowering BP could be applied to almost any population however we are studying IMST in older adults with obstructive sleep apnea (OSA). OSA is an ideal population to target because OSA prevalence is growing and because snoring and apneas result in chronic intermittent hypoxemia that drives sympathetic nervous system (SNS) hyperactivity, endothelial dysfunction and hypertension. These substantive risks for cardiovascular disease are compounded by poor adherence to the mainstay treatment continuous positive airway pressure (<50%), obesity, fatigue and a robust intolerance for exercise.

Our findings in healthy young adults (n=50) show IMST-related reductions in BP are mediated by decreases in systemic vascular resistance, suggesting changes in vascular tone and function. Consistent with this hypothesis, our results from a pilot clinical trial in adults with OSA (n=24) show IMST-related reductions in plasma norepinephrine levels (PNE) and muscle sympathetic nerve activity (MSNA), both markers of SNS activity. Our preliminary mechanistic assessments indicate IMST may lower circulating concentrations of other vasoconstrictor factors and increase nitric oxide (NO)-mediated endothelium-dependent dilation. And, findings in a novel endothelial cell culture model, point to increases in NO and declines in reactive oxygen species (ROS) and oxidative stress. However, it is unknown if: 1) IMST lowers casual and 24-h (ambulatory) SBP in older adults with OSA; 2) the reductions in SBP are long-lasting; 3) arterial stiffness, NO-mediated endothelial dilation and/or oxidative stress are improved; and 4) if adherence in this population is high long term.

In this randomized, double-blind clinical trial we will establish the efficacy of high-intensity IMST (75% maximum inspiratory pressure, [PImax]) 5 days/week for 24 weeks vs. low-intensity IMST (15%PImax) (n=61/group) for lowering SBP in adults (>50 years) with above normal BP and OSA. We hypothesize that IMST will lower SBP via reductions in SNS activity and circulating vasoconstrictor factors, improvements in vascular function, and reductions in oxidative stress/inflammation and that reductions in SBP will be sustained 4 and 12 weeks post-intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

盲法说明

This is a randomized double-blinded clinical trial.

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 50 and older
  • Ability to understand study procedures and to comply with them for the entire length of the study
  • Ability to provide informed consent;
  • Willing to accept random assignment to condition
  • Individuals with who are unwilling or unable to adhere to CPAP
  • Individuals who are adherent to CPAP therapy (i.e., 4 hours/night on 70%/nights over 30 days in the first 3 months of initial usage)
  • Individuals who are adherent to mandibular advancement device each night
  • Above-normal SBP (i.e., SBP ≥120)
  • BMI ≤40 kg/m2
  • Weight stable in the prior 3 months (<3.0 kg weight change) and willing to remain weight stable throughout the study
  • No change in anti-hypertensive medications or other medications (prescription or dosing) in the prior 3 months and willingness to maintain current medication regimen throughout the study
  • Absence of unstable clinical disease as determined by medical history, physical examination, and blood chemistries
  • Total cholesterol <240 mg/dL
  • Fasting plasma glucose <300 mg/dL

排除标准

  • Individuals with central or mixed sleep disordered breathing
  • Severe hypoxemia (<80% for >10% of recording time) during sleep
  • SBP ≥160 or DBP ≥120
  • Current smoker
  • Chronic overt and poorly controlled medical condition (e.g., diabetes, chronic kidney disease, cancer, congestive heart failure)
  • Cheyne-Stokes Respiration
  • Alcohol or illegal drug dependence or abuse
  • Uncontrolled thyroid disease or change in thyroid medication within previous 3 months
  • Regular/vigorous aerobic exercise (> 4 bouts/week, >30 min/bout at high workload >6 METS)

结局指标

主要结局

Change from baseline casual Systolic Blood Pressure at 24 weeks, 28 weeks, and 36 weeks

时间窗: Measured at Baseline, Week 24, Week 28, and Week 36 to establish the intermediate and long-lasting effects of IMST

The primary endpoint is casual (resting) systolic blood pressure (SBP) measured by both relative and absolute changes from baseline. SBP will be assessed in accordance with American College of Cardiology/American Heart Association guidelines. Measurements will be taken using an automated oscillometric sphygmomanometer and will be performed in triplicate over the brachial artery of the non-dominant arm after 5 minutes of quiet rest, with 1 minute of recovery between measures. SBP will be defined as the average of the 3 pressures.

次要结局

  • Change from baseline 24-hour Ambulatory Systolic Blood Pressure at 24 weeks, 28 weeks, and 36 weeks(Measured at Baseline, Week 24, Week 28, and Week 36 to establish the intermediate and long-lasting effects of IMST)
  • Change from baseline Plasma Norepinephrine at 24 weeks, 28 weeks, and 36 weeks(Measured at Baseline, Week 24, Week 28, and Week 36 to establish the intermediate and long-lasting effects of IMST)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elizabeth Fiona Bailey, PhD

Professor

University of Arizona

研究点 (2)

Loading locations...

相似试验